Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis

Atopic Dermatitis Clinical Trial

Official title:

Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on the Effectiveness and Safety of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Moderate to Severe Atopic Dermatitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06026891
• Other study ID #: MG-K10-AD-003
• Status: Recruiting
• Phase: Phase 3
• Start date: January 13, 2024
• Est. completion date: December 12, 2025

Study information

• Verified date: December 2023
• Source: Shanghai Mabgeek Biotech.Co.Ltd
• Contact: xiaofeng Cai, bachelor
• Phone: 02151371305
• Email: xiaofeng.cai[@]mabgeek.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis.administered every 4 weeks for 52 week

Description:

The study was a multicenter, randomized, double-blind, placebo-controlled Phase III study. Approximately 498 adults with moderate-to-severe AD who were not controlled by local therapy were scheduled to receive multiple subcutaneous injections (administered every 4 weeks for 52 weeks). The study was divided into screening period (1-5 weeks), double-blind treatment period (16 weeks), treatment maintenance period (36 weeks), and follow-up period (8 weeks).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 498
• Est. completion date: December 12, 2025
• Est. primary completion date: June 11, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. age 18-75 years (inclusive of 18 and 75 years), both sexes;

2. patients with AD diagnosed in accordance with the American Academy of Dermatology Consensus Criteria (2014), with a pre-screening diagnosis of AD or history of eczema for =1 year, and the following:

• Eczema Area and Severity Index (EASI) score =16 at screening and baseline visit;

• Investigator's Overall Assessment (IGA) =3 points at screening and baseline visit;

• BSA =10% of area of AD involvement at screening and baseline visit

• Weekly mean of peak daily itch NRS score =4 at randomization;

3. the patient had an inadequate treatment effect on topical medication or systemic therapy within 6 months prior to the screening visit, or the use of topical medication or systemic therapy was medically inappropriate

4. negative screening blood pregnancy test results in women of childbearing age;

Exclusion Criteria.

1. subjects with a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) that may interfere with AD evaluation;

2. Patients with ocular disease that, in the judgment of the Investigator, makes enrollment in the study inappropriate, e.g., past history of atopic keratoconjunctivitis with corneal involvement; if the Investigator is unable to make a determination, a diagnosis will be made by an ophthalmologist;

3. those who plan to undergo major surgery during the study period, including inpatient surgery and daytime outpatient surgery;

4. Subjects with the following conditions:

• Persons who have used a biologic agent within 10 weeks prior to randomization or have not exceeded 5 half-lives (whichever is longer); Targeted inhibitors (e.g., JAK inhibitors, etc.), systemic glucocorticoids, cyclosporine and other immunosuppressants (e.g., methotrexate, mycophenolate mofetil [MMF], and azathioprine, etc.), phosphodiesterase (PDE4) inhibitors, ultraviolet light therapy, and systemic herbal medicine for AD within 4 weeks prior to randomization;

• Has received topical glucocorticosteroids, topical calcineurin phosphatase inhibitors, antibiotic compound cream, and topical herbal therapy for AD within 1 week before randomization;

• Has received allergen-specific immunotherapy within 6 months prior to randomization;

• Live/live attenuated vaccination within 3 months prior to randomization or planned for the duration of the study;

• Participation in a clinical study of another drug in the 3 months or 5 half-lives, whichever is longer, prior to randomization or planning to participate in a clinical study of another drug during the study period;

• Subjects with prior use of an interleukin 4 receptor alpha subunit (IL-4Ra) monoclonal antibody drug who, in the judgment of the investigator, have developed drug resistance or drug-related serious AE;

• Previous participation in the MG-K10 clinical trial;

5. evidence of active tuberculosis, or previous evidence of active tuberculosis without appropriate documented treatment; chest X-ray (frontal and lateral) or CT, etc. within 3 months prior to/surrounding the screening period suggesting the presence of active tuberculosis infection;

6. women who are breastfeeding or pregnant, or who plan to become pregnant or breastfeed during the study;

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• MG-K10/Placebo
MG-K10 Humanized Monoclonal Antibody Injection

Locations

Country	Name	City	State
China	Peking University People's Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Mabgeek Biotech.Co.Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportions of subjects achieving EASI-75	Proportions of subjects achieving EASI-75 (= 75% decrease from baseline in EASI	16 weeks
Primary	Proportions of subjects achieving IGA score of 0/1 point and a decrease of = 2	Proportions of subjects achieving IGA score of 0/1 point and a decrease of = 2 points from baseline	16weeks
Secondary	The percentage of subjects who reached EASI-75 at other evaluation points;	The percentage of subjects who reached EASI-75 at other evaluation points;	16 weeks
Secondary	Other evaluation points of view subjects with an IGA score of 0 or 1	Other evaluation points of view subjects with an IGA score of 0 or 1 and a decrease of = 2 points from the baseline	16 weeks
Secondary	Percentage of subjects who reach EASI-50	Percentage of subjects who reach EASI-50 (EASI score is =50% lower than the baseline)	16 weeks
Secondary	Percentage of subjects who reach EASI-90	Percentage of subjects who reach EASI-90 (EASI score is =90% lower than the baseline)	16 weeks
Secondary	Each evaluation point of view EASI	Each evaluation point of view EASI score compared with the baseline change and change rate	16 weeks
Secondary	Percentage of subjects with a decrease of =2	Percentage of subjects with a decrease of =2 points from the baseline IGA score at each evaluation point of view	16 weeks
Secondary	Percentage of subjects with a weekly average of daily peak itching NRS score =3	Percentage of subjects with a weekly average of daily peak itching NRS score =3 points lower than the baseline;	16 weeks
Secondary	The AD of each evaluation visit involves the change and rate of the baseline of BSA;	The AD of each evaluation visit involves the change and rate of the baseline of BSA;	16 weeks
Secondary	The DLQI score of each evaluation interview has changed compared with the baseline.	The DLQI score of each evaluation interview has changed compared with the baseline.	16 weeks
Secondary	The self-evaluation (POEM) score of patients with eczema from each evaluation point of view has changed compared with the baseline;	The self-evaluation (POEM) score of patients with eczema from each evaluation point of view has changed compared with the baseline;	16 weeks
Secondary	The European Five-dimensional Health Scale (EQ-5D)	The European Five-dimensional Health Scale (EQ-5D) at each evaluation point of view is more than the baseline change and rate of change.	16 weeks